Key facts
- This page summarizes Lawrence Otto Klein's Form 3 filing for Jade Biosciences, Inc. (JBIO).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 May 2025, 17:44.
Lawrence Otto Klein - 28 Apr 2025 Form 3 Insider Report for Jade Biosciences, Inc. (JBIO)
- Reporting relationship
- Director
- Issuer ticker
- JBIO
- Reported as of
- 28 Apr 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 01 May 2025, 17:44:19 UTC
- Prior SEC filing
- 24 Jan 2025
- Next SEC filing
- 01 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Balta, as attorney-in-fact for Lawrence Otto Klein
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lawrence Otto Klein filed Form 3 for Jade Biosciences, Inc. (JBIO) on 01 May 2025.
Change
- Previous filing in this sequence was filed on 24 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 86,215
- Date
- 28 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
JBIO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 28 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 48,720
- Exercise price
- $6.03
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Effective as of April 28, 2025 (the "Effective Time"), (i) a wholly-owned subsidiary of Aerovate Therapeutics, Inc. ("Aerovate") merged with and into Jade Biosciences, Inc. ("Jade") with Jade continuing as a wholly owned subsidiary of Aerovate and the surviving corporation of the merger, (ii) immediately thereafter, Jade merged with and into a second wholly-owned subsidiary of Aerovate ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger and (iii) immediately thereafter, Second Merger Sub merged with and into Aerovate, with Aerovate being the surviving entity of the merger (collectively, the "Merger"). At the Effective Time, Aerovate changed its name to "Jade Biosciences, Inc." (hereinafter, the "Issuer").
Footnote F2
Represents the number of shares of restricted common stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of restricted common stock of Jade held by the Reporting Person prior to the Merger. Each share of restricted common stock of Jade held at the Effective Time was exchanged for 0.6311 shares of the Issuer's restricted common stock.
Footnote F3
Consists of 86,215 shares of restricted common stock, one quarter of which will vest on July 23, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Footnote F4
This option represents a right to purchase 48,720 shares of the Issuer's common stock, one quarter of which will vest on January 29, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
SEC remarks
Exhibit 24 - Power of Attorney